Bart Klein

Bart Klein has had an extensive career in the pharmaceutical and biotechnology industry, with a focus on intellectual property and innovation. Bart began their career as a Patent Officer at MOGEN International in 1990 and later became a Senior Patent Attorney at Gist-Brocades B.V. in 1995. In 1998, they joined KPN Telecom B.V. as the Head of the Intellectual Property Group. After that, they served as the EVP of IP & Legal at Crucell from 2001 to 2012. In 2012, they took on various roles, including being a Board Member at HollandBIO, a Member of the Strategy Board at Aglaia BioMedical Ventures, and a Member of the supervisory board at DC Prime. In 2013, they founded and directed Primetime Biosciences B.V. before joining ProQR Therapeutics NV in 2014. At ProQR, they held positions such as Senior VP IP & Innovation, Senior VP IP and Technology Development, and currently serves as Senior VP Innovation.

Bart Klein attended IMD in 1999, where they studied Managing Corporate Resources. Bart also attended IMD in the same year, although the field of study is not specified. From 1993 to 1995, Bart Klein studied Intellectual Property Law at European Patent Attorney, earning the degree of EPA. Prior to that, from 1990 to 1993, they studied Intellectual Property Law at Dutch Patent Attorney, earning the degree of DPA. In 1988, Bart Klein studied Russian at SMID. Bart completed their undergraduate studies at Utrecht University from 1982 to 1988, earning a Msc in Chemical Biology. Prior to university, Bart Klein attended Maurick College, but no specific details about their field of study were provided.